Full Title
F8294-201b: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Study Treatment
Oral BRAF inhibitor FORE8394 in combination with cobicistat
Eligibility/Info
For the treatment of patients with a BRAF V600E mutant CNS primary malignancy that has recurred or continued to grow after at least 1 prior line of therapy including radiation.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
